Barbara S. Schilberg
Managing Director @ BioAdvance
Barbara S. Schilberg is a seed investor at BioAdvance focused on Health Care and Hardware. Ms. Schilberg has more than 30 years of experience working with academic technologies and start-up companies in the life sciences sector. Under her leadership as CEO, BioAdvance has committed $24.2 million to 36 seed-stage companies and 21 pre-seed projects focusing in areas including Alzheimer's disease, cancer, diabetes, obesity andinfectious diseases. The BioAdvance portfolio companies have leveraged $1.6 billion in subsequent capital from venture capital, grants, collaborations, M&A activity and product revenues. Eight portfolio companies have been acquired, one company has completed an initial public offering, and one exited through a refinancing. Ms. Schilberg is a board member or serves as an observer on the boards of several BioAdvance portfolio companies including Immunome, Jenrin Discovery, Melior Pharmaceuticals, Novira Pharmaceuticals and QR Pharma. As a senior executive with four emerging life sciences companies, Ms. Schilberg's prior experience provides significant insight into the key elements needed to build successful companies including public and private financings, intellectual property protection, corporate partnering arrangements and the management of research programs. She joined Cephalon in 1994 as Senior Vice President and General Counsel and as a member of the executive committee. As part of her responsibilities, she led a multi-disciplinary team charged with completing Phase III clinical trials and preparing a new drug application for PROVIGIL® (modafinil), which was approved by the FDA in December 1999. She joined Incara Pharmaceuticals in 1998 as Executive Vice President and General Counsel, where she managed a research operation in Princeton, NJ engaged in discovering new antibacterial therapeutics. She continued in that capacity after the operation's acquisition by Advanced Medicine (now Theravance) in 2000. Ms. Schilberg also served as Vice President and General Counsel at Locus Discovery, Inc., an emerging pharmaceutical company in Blue Bell, PA engaged in computational drug design.Before joining industry, Ms. Schilberg specialized in representing biopharmaceutical companies and research institutions in the commercialization of technology, as a partner in the Philadelphia office of Morgan, Lewis & Bockius. Ms. Schilberg received a J.D. from the University of Virginia and clerked with the Honorable Edward R. Becker, now Senior Judge of the U.S. Court of Appeals for the Third Circuit.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries Barbara S. Schilberg invests in
Stages Barbara S. Schilberg invests in
Countries Barbara S. Schilberg invests in
Investment Focus
Industry
- Health Care 2 (67%)
- Hardware 1 (33%)
- Analytics 1 (33%)
- Child Care 1 (33%)
- Smart Home 1 (33%)
Stage
- Seed 2 (67%)
- Series A 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Pillo Health
|
Pillo Health provides HIPAA compliant tools for caregivers and health organizations to deliver better care to loved ones and patients living at home. The company's care delivery platform is centered on an intelligent healthcare assistant called Pillo. In addition to managing medications, Pillo can provide patients at home with health andwellness information, can proactively deliver digital care plans into the home, and can connect the home to care teams via smart notifications and video calling. The company also offers an SDK for partner organizations to create their own unique skills for Pillo by leveraging the company's proprietary in home voice first device. | $11M / Series A / May 29, 2019 | |
|
Pillo Health
|
Pillo Health provides HIPAA compliant tools for caregivers and health organizations to deliver better care to loved ones and patients living at home. The company's care delivery platform is centered on an intelligent healthcare assistant called Pillo. In addition to managing medications, Pillo can provide patients at home with health andwellness information, can proactively deliver digital care plans into the home, and can connect the home to care teams via smart notifications and video calling. The company also offers an SDK for partner organizations to create their own unique skills for Pillo by leveraging the company's proprietary in home voice first device. | $1.5M / Seed / Feb 17, 2017 | |
Keriton Inc
|
Every year around 500,000 infants are admitted to one of the 1,100+ Neonatal ICUs (NICUs) across US. While mother's breast milk is important for all newborns, it is vital for the survival of these fragile patients. However, despite its critical role, the current state of breast milk management in NICUs is extremely manual, labor-intensive anderror prone. Keriton is working with Penn Medicine to develop a new gold-standard for breast milk management. With end-to-end process automation and validation, Keriton's HIPAA-compliant SaaS suite significantly lowers the nurses’ time spent on breast milk management, reduces errors and automatically generates an audit trail for the process. The Keriton suite also aims to improve expression of breast milk in lactating NICU mothers by enhancing their pumping experience, which has been empirically linked to improved clinical outcomes. Keriton delivers on all 3 aspects of AHA's triple goals i.e. improved outcomes, reduced cost and better patient engagement with a possible ROI of $4.5M per average sized NICU. | $1M / Seed / Feb 16, 2017 |
Co-Investors
About BioAdvance
BioAdvance provides funding to startup life sciences companies in Southeastern Pennsylvania through its new $50 million Greenhouse Fund. They invest in therapeutics, devices, diagnostics and platform technologies focused on human health.Since its first investments in 2003, BioAdvance has become one of the nation's leading investorsproviding pre-seed and seed-stage funding. To date they have committed more than $40 million to more than 50 seed-stage companies and 17 pre-seed companies. Their portfolio companies are working to develop products to treat health problems including Alzheimer's disease, cancer, obesity, GI disorders, neurological and respiratory illnesses. BioAdvance was established with $33 million from the Commonwealth of Pennsylvania's share of tobacco settlement monies.
BioAdvance Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Shahram Hejazi
Partner
|
|||
|
Barbara S. Schilberg
Managing Director
|
|||
Frederick Jones
Partner
|
|||
Gregory Harriman
Partner and Chief Investment Officer
|
|||
Jeff Edelson
Entrepreneur in Residence / Scientific Liason
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Barbara S. Schilberg invest in?
Barbara S. Schilberg invests primarily in Health Care, Hardware and Analytics startups, most often at Seed and Series A stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Barbara S. Schilberg last invest?
The most recent investment recorded for Barbara S. Schilberg closed in May 2019. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
